It can assess patients’ suitability for Amgen’s colorectal cancer drug, Vectibix. Canadian regulatory authorities approved DxS’ TheraScreen K-RAS Mutation Kit for use as a diagnostic for anti-EGFR ...

Company will work with ImClone and BMS to develop FDA-approved test for mCRC patients. DxS is to work with ImClone Systems and Bristol-Myers Squibb on the development of a companion diagnostic for the ...

The US Food and Drug Administration (FDA) has granted approval for EntroGen's CRCdx RAS Mutation Detection Kit as a companion diagnostic for Vectibix (panitumumab), a targeted therapy used in the ...

DxS has announced that lung cancer patients who have acquired gene mutations associated with resistance to tyrosine kinase inhibitors such as Iressa or Tarceva can be identified accurately using a ...

Toxicity differences in CDK 4/6 inhibitors seen in Asian and Pacific Islanders. Real-world treatment patterns and clinical outcomes among patients with HR+/HER2- advanced/metastatic breast cancer ...

The splicing of nuclear pre-mRNA is a fundamental process for the expression of most metazoan genes. More than half of reported exonic mutations in human disease and cancers are due to ...

Dublin, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The "Mutation Detection Kits in Genome Editing Market Report 2025" has been added to ResearchAndMarkets.com's offering. The mutation detection kits in the ...

OMAHA, Neb., April 14, 2011 /PRNewswire/ -- Transgenomic, Inc. (OTC/BB: TBIO) announced today that it has launched kits for high sensitivity mutational analysis of the BRAF and PIK3CA genes. These new ...

Researchers working on an incurable blood cancer can now use a new lab model that could make testing potential new treatments and diagnostics easier and quicker, new research has found. Subscribe to ...

Progressing lesions of 25 patients with GISTs refractory to ripretinib were sequenced for KIT resistance mutations. Resistant genotypes were validated and characterized using novel cell line models ...